

**REMARKS**

All claims that were rejected under Section 103(a) have been cancelled without prejudice to their future pursuit. The remaining claims have been amended to put them in independent form. They were each indicated as allowable if put in independent form.

In addition, claim 38 has been amended to recite that the tumor is a pancreatic tumor and that the patient develops an increased DTH response to autologous tumor cells after administration of the composition. This is supported at Table 2, page 33.

**The Rejection of Claim 38 Under 35 U.S.C. §112, First Paragraph**

Claims 38 as amended stands rejected under 35 U.S.C. §112, first paragraph as not supported by the specification. This rejection is respectfully traversed.

Claim 38 as amended was objected to because 60 month tumor-free survival as only demonstrated in pancreatic cancer patients and of these, only in a subset. Claim 38 has been amended to recite pancreatic cancer and to specify that the patient exhibits increased DTH to autologous tumor cells after administration of the composition. It is respectfully submitted that claims 38 as amended is fully supported by the disclosure, particular at Table 2, page 33. Withdrawal of this rejection is therefore respectfully requested.

**The Rejection of Claims 22-25, 27-34, 37, 111, 114, 116-121 Under 35 U.S.C. §103(a)**

Claims 22-25, 27-34, 37, 111, 114, 116-121 were rejected under 35 U.S.C. §103(a) over two combinations of references. Each of these claims has been cancelled without prejudice to expedite issuance of the remaining claims. These rejections under § 103(a) are now moot.

A speedy allowance of the claims is requested.

Dated: February 27, 2009

Respectfully submitted,

By: /Sarah A. Kagan/  
Sarah A. Kagan  
Registration No.: 32,141

Banner & Witcoff, Ltd.  
Customer No. 22907